Acadia
is a California-based biopharmaceutical company that discovers and develops novel therapies for the treatment of Parkinson’s disease... Read moreAcadia
is a California-based biopharmaceutical company that discovers and develops novel therapies for the treatment of Parkinson’s disease... Read more
News
Jul 11, 2026
Nasdaq
Acadia: An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Jun 29, 2026
Pharmabiz
Acadia: EMA committee recommends marketing approval for Acadia Pharma's Daybu to treat neurobehavioral symptoms of Rett syndrome
Jun 26, 2026
FinanzNachrichten
Acadia: Acadia Pharmaceuticals Inc.: DAYBU (trofinetide) Recommended for Approval in the European Union by CHMP
Jun 26, 2026
Investors Business Daily
Acadia: The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout
Jun 26, 2026
BioPharma Dive
Acadia: On second try, Acadia drug gets nod from European regulators
Jun 10, 2026
Law 360
Acadia: Acadia Pharma Must Face Investors' Drug Approval Claims
May 28, 2026
Benzinga
Acadia: Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock
May 18, 2026
NashvillePost
Acadia: Acadia stock remains under pressure despite revenue growth
May 11, 2026
Yahoo
Acadia: Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts
May 07, 2026
Owler
Acadia Pharmaceuticals, Inc.: Acadia's revenue changed from $1.07B in Dec 2025 to $1.10B in Mar 2026
